Influence of molecular weight on passive tumour accumulation of a soluble macromolecular drug carrier

European Journal of Cancer

Volumn 31, Issue 5, 1995, Pages 766-770

  Seymour, L W ^a   Miyamoto, Y ^b   Maeda, H ^b   Brereton, M ^d   Strohalm, J ^c   Ulbrich, K ^c   Duncan, R ^a  

^a KEELE UNIVERSITY   (United Kingdom)

^b KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

^c INSTITUTE OF MACROMOLECULAR CHEMISTRY   (Czech Republic)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

N (2 hydroxypropyl)methacrylamide copolymers; polymer conjugates; targeting; vascular permeability

Indexed keywords

DRUG CARRIER; N (2 HYDROXYPROPYL)METHACRYLAMIDE; POLYMER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL PERMEABILITY; CONTROLLED STUDY; DRUG TARGETING; DRUG UPTAKE; INTRAVENOUS DRUG ADMINISTRATION; MALE; MELANOMA; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PRIORITY JOURNAL; SARCOMA;

ACRYLAMIDES; ANIMAL; DRUG CARRIERS; IODINE RADIOISOTOPES; MACROMOLECULAR SYSTEMS; MALE; MELANOMA; METABOLIC CLEARANCE RATE; MICE; MOLECULAR WEIGHT; NEOPLASMS, EXPERIMENTAL; SARCOMA, EXPERIMENTAL; SUPPORT, NON-U.S. GOV'T; TUMOR CELLS, CULTURED;

EID: 0029039418     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(94)00514-6     Document Type: Article

References (29)

1. Design of compounds having an increased tumour uptake, using serum albumin as carrier. Part 1
2. A lipophilic derivative of neocarzinostatin: a polymer conjugation of an antitumour protein antibiotic
3. Tailor-making of protein drugs by polymer conjugation for tumor targeting: a brief review on smancs
4. The tumour blood vessel as an ideal site for macromolecular anticancer agents
5. Activity of N-(2-hydroxypropyl)methacrylamide copolymers containing daunomycin against a rat tumour model
6. Tumouritropism and anticancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma
7. Passive tumour targeting of soluble macromolecules and drug conjugates
8. A new concept for macromolecular therapeutics in cancer therapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS
9. Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo
10. Effect of arterial administration of high molecular weight anticancer agent SMANCS with lipid lymphographic agent on hepatoma: a preliminary report
11. Targeting chemotherapy for hepatoma: arterial administration of anticancer drugs dissolved in Lipiodol
12. Antitumour effects of SMANCS on rat mammary tumor induced by 7, 12-dimethylbenz[a]anthracene
13. SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy
14. Augmentation of tumour delivery of macromolecular drugs with reduced bone marrow delivery by elevating blood pressure
15. Drug-polymer conjugates: potential for improved chemotherapy
16. Effect of molecular weight of N-(2-hydroxypropyl)methacrylamide copolymers on body distribution and rate of excretion after subcutaneous, intraperitoneal and intravenous administration to rats
17. Targeting of N-(2-hydroxypropyl)methacrylamide copolymers to liver by incorporation of galactose residues
18. Reactive copolymers of N-(2-hydroxypropyl)methacrylamide with N-methacryloylated derivatives of l-leucine and l-phenylalanine. II. Reaction with the polymeric amine and stability of the crosslinks towards chymotrypsin
19. Synthetic polymers conjugated to monoclonal antibodies: vehicles for tumourtargeted drug delivery
20. N-(2-Hydroxypropyl)methacrylamide copolymers targeted to the hepatocyte galactose-receptor: pharmacokinetics in DBA2 mice
21. The therapeutic values of poly(ethylene glycol)-modified proteins
22. Soluble polymeric carriers for drug delivery-part 4: tissue autoradiography and whole body distribution of N-(2-hydroxypropyl)methacrylamide copolymers following intravenous administration
23. Doxorubicin conjugated with a monoclonal antibody directed to a human melanoma-associated proteoglycan suppresses the growth of established tumour xenografts in nude mice
24. Biodistribution of a monoclonal antibody (RNL-1) against the neural cell adhesion molecule (NCAM) in athymic mice bearing human small-cell lung-cancer xenografts
25. Immunotargeting of human small cell lung cancer xenografts in athymic mice using a monoclonal antibody (RNL-1) against a neuroendocrine-related antigen
26. Disposition characteristics of macromolecules in tumour-bearing mice
27. Tumouritropic and lymphotropic principles of macromolecular drugs